{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-25-005355","form_type":"8-K","ticker":"BYSI","cik":"0001677940","company_name":"BeyondSpring Inc.","filed_at":"2025-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.617040+00:00","generated_at":"2026-05-17T13:57:16.454904+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Q2 net loss narrows to $1.9M; Plinabulin shows 23% ORR in ICI-refractory cancers","bullets":["Net loss from continuing operations $1.9M for Q2 2025 vs $2.7M in Q2 2024; cash $9.5M as of Jun 30, 2025 vs $2.9M Dec 2024.","R&D expenses $1.0M; G&A $0.9M, down from $1.8M on lower headcount and professional costs.","Plinabulin combo in PD-1/L1 progressed NSCLC showed median PFS 6.8 mo, ORR 18.2%, DCR 77%, OS 78% at 15 mo.","SEED Therapeutics' RBM39 degrader ST-01156 cleared FDA IND; Dr. Bill Desmarais appointed CFO and CBO.","Discontinued operations loss $2.8M vs $1.4M YoY, reflecting SEED reporting change."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-25-005355","json":"https://secwatch.observer/filing/0001171843-25-005355.json","markdown":"https://secwatch.observer/filing/0001171843-25-005355.md","text":"https://secwatch.observer/filing/0001171843-25-005355.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1677940/000117184325005355/0001171843-25-005355-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1677940/000117184325005355/f8k_081325.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T13:57:16.454904+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}